Video: Leading the Alpha Charge – with Øystein Soug

From the Norwegian Air Force to alpha-emitting radiopharmaceuticals, Øystein Soug has taken the unconventional route to biotech leadership

1

Øystein Soug leads Oncoinvent after a career spanning military training, finance roles in Russia and China, and more than a decade as a CFO.
2

Oncoinvent is developing Radspherin, a receptor-independent alpha-emitting radiopharmaceutical for cancers that have spread to the abdominal cavity.
3

Radspherin is delivered directly into the peritoneum to concentrate radiation around residual cancer cells while limiting exposure elsewhere in the body.
4

Soug discusses lessons from helping bring Xofigo to market and identifies manufacturing and supply chains as persistent radiopharmaceutical challenges.
5

Soug also discusses new isotopes, delivery methods, combination strategies, Oslo’s radiopharmaceutical sector, and the practical demands of leadership.

1